KCNA3 and Alzheimer disease: Following long-term treatment of an APP/PS1 mouse model, the selective Kv1.3 blocker PAP-1 mitigated some key AD-like phenotypes such as reducing Aβ deposition as well as restoring hippocampal synaptic plasticity.